11 results about "Crospovidones" patented technology

This invention relates to the field of food biotechnology, and more particularly to a selenium-enriched asparagus tea lozenge, its preparation method, and its application. Specifically, it comprises the following components in parts by weight: 60-90 parts selenium-enriched asparagus tea fermentation powder, 10-30 parts mannitol, 0.5-3 parts citric acid, 0.3-2 parts sodium carboxymethyl starch, 1-4 parts crospovidone, 0.05-0.5 parts menthol, and 0.1-1.5 parts magnesium stearate. The selenium-enriched asparagus tea lozenge prepared by this invention has a significant effect on improving sleep. In a zebrafish insomnia model, this lozenge effectively alleviated the hyperactivity induced by insomnia-inducing agents, significantly reduced the movement distance of the model animals, and showed a significant and stable sleep improvement effect, indicating that this lozenge has good application prospects in improving sleep.

The invention provides an Iguratimod tablet and a preparation method thereof. The iguratimod tablet is prepared from iguratimod, mannitol, polyvinylpolypyrrolidone, poloxamer, magnesium stearate and the like, and the preparation method comprises the following steps: dissolving or dispersing the poloxamer and the iguratimod in purified water, spraying into a fluidized bed, and performing one-step granulation together with proper pharmaceutic adjuvants; and drying, adding a lubricant, mixing, and tabletting. The iguratimod tablet prepared by the preparation method disclosed by the invention is good in stability and relatively good in dissolution effect; the method is simple in process, easy to operate and suitable for industrial production.

The invention relates to the technical field of pharmaceutical preparations, in particular to a methylprednisolone pulse micro-tablet and a preparation method thereof. The methylprednisolone pulse microtablet comprises a quick release tablet core and a coating layer, the quick-release tablet core comprises methylprednisolone, a filler, an antistatic agent A, an antistatic agent B, an adhesive and a lubricant; the coating layer comprises a coating material and a plasticizer; wherein the antistatic agent A is selected from at least one of a combination of organic acid and bicarbonate or ammonium carbonate; the antistatic agent B is selected from at least one of polyoxyethylene, carbomer, high-expansion type pregelatinized starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, croscarmellose sodium and crospovidone. The antistatic agent A and the antistatic agent B have a synergistic effect, so that the electrostatic phenomenon can be effectively reduced, and particle adhesion and microchip agglomeration are avoided.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a pellet tablet and a preparation method thereof. The invention relates to a preparation method of a pellet tablet, which comprises the following operation steps of: under the condition of a 100,000-grade clean area, preparing main medicine fine powder into particles with certain plasticity, sieving the whole particles to obtain pellet particles, mixing the pellet particles and auxiliary materials according to the mass ratio of the auxiliary materials to the pellet particles being 1: (2-6) to prepare the tablet, disinfecting the tablet, and packaging in vacuum to obtain the pellet tablet. The pellet tablets are obtained; the auxiliary materials comprise croscarmellose sodium, silicified crospovidone, microcrystalline cellulose, mannitol and sodium stearyl fumarate. The release curve of the pellet tablet is basically consistent with that of the pellet, the release end point can still reach 100%, it is indicated that the protection effect on the pellet can be remarkably enhanced through the preparation method of the pellet tablet, the minimum tensile strength of the obtained pellet tablet is 78.6 kPa, and the fracture resistance of the pellet in the tabletting process is improved.

This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a lozenge for refreshing the mind and freshening the breath, and its preparation method. The lozenge comprises a plain tablet and a shell. The plain tablet includes inner phase particles, an inner phase particle coating layer, and excipients: the inner phase particles use sodium carboxymethyl cellulose and crospovidone to construct an immediate-release framework, with immediate-release and sustained-release caffeine and theanine as stimulating ingredients, supplemented by poloxamer to enhance penetration, achieving rapid absorption and sustained release of caffeine, and the theanine alleviates the nerve stimulation caused by caffeine; the inner phase particle coating layer uses hydroxypropyl methylcellulose and hydroxypropyl cellulose to construct a sustained-release framework, with polyethylene glycol forming microporous channels to promote the sustained release of fermented ginsenosides, enhancing anti-fatigue ability to prolong the stimulating effect, and releasing eucalyptol and limonene to produce a cooling sensation and mask odor, supplemented by Lactobacillus rhamnosus to inhibit the growth of harmful bacteria in the mouth to reduce odor, thereby achieving the effects of rapid stimulating, long-lasting mental alertness, and fresh breath.

The present invention provides a pharmaceutical composition which is a tablet containing tafamidis free acid, one or more diluents, a disintegrant of 7 - 9% (w / w%) and a lubricant. A typical example is a tablet containing about 11.6% (w / w%) of tafamidis free acid; about 53.1% (w / w%) of microcrystalline cellulose; about 26.55% (w / w%) of lactose monohydrate; about 8.0% (w / w%) of crospovidone type b and about 0.75% (w / w%) of magnesium stearate. 【Figure 1】 TIFF2025524085000013.tif161105

The invention discloses a lamotrigine composition and a preparation process thereof. The lamotrigine composition is prepared from the following raw materials in mass concentration: 20-40% of lamotrigine, 30-40% of lactose monohydrate, 30-40% of microcrystalline cellulose, 1-4% of a disintegrating agent and 0.3-1% of magnesium stearate, and the total amount is 100%. The disintegrating agent is polyvinylpolypyrrolidone or sodium carboxymethyl starch. According to the lamotrigine composition provided by the invention, novel direct-mixing type auxiliary materials are adopted, the formula composition is simplified under the condition that the same in-vitro release target as a reference preparation is achieved, and the qualification of a product is further improved. According to the invention, a direct-mixing tabletting process is adopted, so that the production process is greatly simplified, and the production cost is reduced; water vapor and high temperature are avoided in the production process, and the stability of the product is ensured; the lamotrigine tablet prepared by the process has the advantages of uniform weight, complete appearance, no sticking and top cracking and the like, and is suitable for industrial production.

An orodispersible tablet comprising 40-60%w / w carbamazepine, at least one diluent and at least one pharmaceutically acceptable excipient. The orally disintegrating tablet may be produced by the wet gr

The application discloses an antihypertensive compound preparation, which comprises 4.0% benazepril hydrochloride, 5.0% hydrochlorothiazide, 78-82% diluent, 6-11% disintegrant, 2-3% lubricant and coating material in percentage by weight. The diluent is selected from one or more of lactose and microcrystalline cellulose, the ratio of the amount of lactose to the amount of microcrystalline cellulose is (10-13):(1-2), the disintegrant is crospovidone, the lubricant is hydrogenated castor oil, and the particle size of benazepril hydrochloride and hydrochlorothiazide is D90<70 mu m. The benazepril hydrochloride and hydrochlorothiazide tablet provided by the application has good stability and dissolution performance.

This invention discloses a dual-enzyme anhydrous compounded acid-base rapid-disintegration porous toothpaste, belonging to the field of oral care product technology. The toothpaste is composed of the following raw materials: 9.0 parts sodium bicarbonate, 4.5 parts anhydrous citric acid, 6.0 parts crospovidone, 27.5 parts microcrystalline cellulose, 1.5 parts embedded complex biological enzyme, 3.5 parts powdered sodium lauroyl sarcosinate, 1.5 parts powdered sodium cocoyl glutamate, 22.0 parts spherical micro-powdered hydrated silica, 0.75 parts sodium monofluorophosphate, 1.5 parts anhydrous sodium pyrophosphate, 7.0 parts low-hygroscopic sorbitol, 0.2 parts sucralose, 0.8 parts pre-adsorbed peppermint flavor, 0.75 parts magnesium stearate, and 0.5 parts powder-embedded phenoxyethanol. This invention utilizes an anhydrous powder formulation design, taking advantage of the synergistic disintegration effect of an acid-base effervescent system and cross-linked polyvinylpyrrolidone, combined with the chemical decomposition of plaque biofilm by microencapsulated dual enzymes, to achieve rapid disintegration of the lozenge in the mouth and release of micro-nano bubbles. It can complete oral cleaning without the need for toothbrush friction, and is characterized by being gentle, portable, rapid disintegration and leaving no residue.

Orally disintegrating tablet (ODT) comprising: amlodipine or pharmaceutically acceptable salts thereof, at 2-10%w / w (e.g., 4-8%w / w); at least one diluent (e.g., microcrystalline cellulose (5-25%w / w) a